Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;61(1):12-16.
doi: 10.1111/trf.16119. Epub 2020 Oct 14.

Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations

Affiliations

Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations

Christof Jungbauer et al. Transfusion. 2021 Jan.

Abstract

Background: Transfusion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma is a promising treatment for severe coronavirus disease 2019 (COVID-19) cases, with success of the intervention based on neutralizing antibody content. Measurement by serologic correlates without biocontainment needs as well as an understanding of donor characteristics that may allow for targeting of more potent donors would greatly facilitate effective collection.

Study design and methods: One hundred convalescent plasma units were characterized for functionally active SARS-CoV-2 neutralizing antibodies, as well as for SARS-CoV-2 binding antibodies, with the intention to establish a correlation between the functionally more relevant neutralization assay and the more accessible enzyme-linked immunosorbent assay (ELISA). Donor demographics such as COVID-19 severity, age, and sex were correlated with antibody titers.

Results: A mean neutralization titer 50% of 230 (range, <8-1765) was seen for the 100 convalescent plasma units, with highly significant (P < .0001) yet quantitatively limited (R2 = 0.2830) correlation with results of the ELISA. Exclusion of units with particularly high titers (>500) from analysis improved correlation (R2 = 0.5386). A tendency of higher-titer plasma units from donors with increased disease severity, of advanced age, and of male sex was seen, yet the functional relevance of this difference is questionable.

Conclusion: The ELISA-based correlation to neutralization titer enabled a threshold proposal that could be used to eliminate lower-titer units from the clinical supply for COVID-19 treatment. Disease severity may be associated with the development of higher titers of neutralizing antibodies, although larger case numbers will be needed for additional confirmation.

Keywords: COVID-19; ELISA correlation; convalescent donor selection; severe acute respiratory syndrome coronavirus 2; virus neutralization.

PubMed Disclaimer

Conflict of interest statement

M.R.F., E.G.‐R., and T.R.K. are employees of Baxter AG, Vienna, Austria, now part of the Takeda group of companies. M.R.F. and T.R.K. have Takeda stock interest. All other authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Characterization of 100 convalescent plasma donations collected at the Vienna Blood Centre for (A) SARS‐CoV‐2 neutralizing antibody content, reported as log2 microneutralization titers 50% (X) plotted against the relative frequency (percent) of occurrence. B, NT50 titers were correlated against Euroimmun IgG ELISA signal ratios obtained for the same donations [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
COVID‐19 convalescent plasma donor demographics illustrating (A), correlation of SARS‐CoV‐2 neutralizing antibody titers (NT50) with donor age and (B) difference in NT50 between female and male donors

Similar articles

Cited by

References

    1. Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir Ther. 2018;23:617–622. - PubMed
    1. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. - PMC - PubMed
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID‐19 with convalescent plasma. JAMA. 2020;323:1582–1589. - PMC - PubMed
    1. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID‐19 patients. Proc Natl Acad Sci USA. 2020;117:9490–9496. - PMC - PubMed
    1. Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID‐19: A propensity score‐matched control study. Nat. Med. 2020; 10.1038/s41591-020-1088-9. - DOI - PubMed